Frontiers in Molecular Biosciences · 2020 · 19 citations · 52 references
Life SciencesBiochemistryMolecular BiologyGlycobiologyProtein BiochemistryStructural BiologyAmyloid FormationGlycan StructureN-linked GlycosylationProtein AggregationProtein Aggregation DisordersProtein GlycosylationAdvanced Glycation End ProductsAggregate MorphologyAggregationAmyloid Beta AggregationBiophysical AssaysBiophysical CharacterizationCircular DichroismGlycosylation In Disease
Epidemiological evidence shows an increased risk for developing Alzheimer's disease in people affected by diabetes, a pathology associated with increased hyperglycemia. A potential factor that could explain this link could be the role that sugars may play in both diseases under the form of glycation. Contrary to glycosylation, glycation is an enzyme-free reaction that leads to formation of toxic advanced glycation end-products (AGEs). In diabetes, the islet amyloid polypeptide (IAPP or amylin) is found to be heavily glycated and to form toxic amyloid-like aggregates, similar to those observed for the Aβ peptides, often also heavily glycated, observed in Alzheimer patients. Here, we studied the effects of glycation on the structure and aggregation properties of IAPP with several biophysical techniques ranging from fluorescence to circular dichroism, mass spectrometry and atomic force microscopy. We demonstrate that glycation occurs exclusively on the N-terminal lysine leaving the only arginine (Arg11) unmodified. At variance with recent studies, we show that the dynamical interplay between glycation and aggregation affects the structure of the peptide, slows down the aggregation process and influences the aggregate morphology.
52
Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
Alfredo Lorenzo, Bronwyn L. Razzaboni, Gordon C. Weir et al. · Nature · 1994 · 826 citations
Theodore W. C. Lo, Marie Westwood, Antony C. McLellan et al. · Journal of Biological Chemistry · 1994 · 695 citations · Full text